Table 1.
Inhibition of virus replication
| Drug | HSV-1 | HSV-1-deltaTK | HSV-2 | VV | Ad4 | HCMV | MV | IV |
|---|---|---|---|---|---|---|---|---|
| Olomoucine II | 5.0 ±0.9 | 5.3 ±0.9 | 4.7 ±1.0 | 3.8 ±1.3 | 2.4 ±1.3 | 3.2 ±1.6 | >20 | >20 |
| Roscovitine | >20 | >20 | >20 | >20 | 3.1 ±1.6 | 4.9 ±2.2 | >20 | >20 |
| Iododeoxyuridine | - | - | - | 3.7 ±1.6 | - | - | - | - |
| Acyclovir | 0.5 ±0.2 | 73.0 ±18 | 2.2 ±0.5 | - | - | - | - | - |
| Cidofovir | - | - | - | - | 16.6 ±2.9 | 0.2 ±0.1 | - | - |
| Ribavirin | - | - | - | - | >40 | - | 12.0 ±1.1 | 10.5 ±1.8 |
| Chloroquine | - | - | - | - | - | - | - | 5.3 ±0.9 |
Values ar 50% inhibitory concentrations (IC50; μM) ±SD established by plaque reduction assays (n=4). Ad4, human adenovirus type-4; HCMV, human cytomegalovirus; HSV-1, herpes simplex virus type-1; HSV-2, herpes simplex virus type-2; HSV-1-deltaTK, HSV-1 strain 17 containing green fluorescent protein in the thymidine (TK) locus; IV, influenza virus; MV, measles virus; VV, vaccinia virus Western Reserve strain encoding influenza PB2 in the TK locus.